Eli Lilly & Co. (LLY) Tops Q1 EPS by 10c; Raises guidance

Eli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $2.58, $0.10 better than the analyst estimate of $2.48. Revenue for the quarter came in at $8.77 billion versus the consensus estimate of $8.94 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2024 EPS of $13.50-$14.00, versus the consensus of $12.50. Eli Lilly & Co. sees FY2024 revenue of $42.4-43.6 billion, versus the consensus of $41.44 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
• Lucid reports Q2 output, names new CFO and five other leaders
• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS